C. Fernandes, Ye' Zaw Phyo, João Ribeiro, S. Cravo, M. Tiritan, Artur M. S. Silva, A. Kijjoa, M. Pinto
{"title":"山酮类手性衍生物在药物化学和液相色谱中的双重应用","authors":"C. Fernandes, Ye' Zaw Phyo, João Ribeiro, S. Cravo, M. Tiritan, Artur M. S. Silva, A. Kijjoa, M. Pinto","doi":"10.3390/ecmc-4-05604","DOIUrl":null,"url":null,"abstract":"Over several years, xanthone derivatives have been the core of several studies, essentially due their wide range of biological and pharmacological activities [1]. Recently, chiral derivatives of xanthones (CDXs) have come to arouse great interest considering enantioselectivity studies associated with biological activities [2,3] as well as selectors for chiral stationary phases (CSPs) in liquid chromatography (LC) [4,5]. \nFrom the perspective of Medicinal Chemistry, some CDXs synthetized by our group revealed interesting biological activities [2,3]. Besides the potential as new drugs, CDXs afford promising LC enantioresolution results [6]. \nIn a continuation of our study, new enantiomerically pure CDXs were synthetized for biological activity evaluation as well as selectors for new CSPs, confirming that CDXs have important applications not only in the field of Medicinal Chemistry but also for analytical applications. \nAcknowledgements: \nThis research was partially supported by the Strategic Funding UID/Multi/04423/2013 and UID/QUI/00062/2013 through national funds provided by FCT and ERDF, in the framework of PT2020, by projects PTDC/MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599-PPCDT), and project No. POCI-01-0145-FEDER-028736, co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF, and by FCT through national funds, as well as by the Portuguese NMR Network, and CHIRALXANT-CESPU-2018. \n \n[1] Shagufta, A.I. Eur. J. Med. Chem., 2016, 116, 267-280. \n[2] Fernandes, C. et al. Bioorg. Med. Chem. 2014, 22, 1049-1062. \n[3] Fernandes, C. et al. Pharmaceuticals, 2017, 10, 50, doi:10.3390/ph10020050. \n[4] Phyo, Y.Z. et al. Molecules, 2018, 23, 142, doi:10.3390/molecules23010142. \n[5] Carraro, M.L. et al. Chirality, 2017, 1–10 \n[6] Fernandes, C. et al. Chirality, 2017, 29(8),430-442.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual application of chiral derivatives of xanthones in medicinal chemistry and liquid chromatography\",\"authors\":\"C. Fernandes, Ye' Zaw Phyo, João Ribeiro, S. Cravo, M. Tiritan, Artur M. S. Silva, A. Kijjoa, M. Pinto\",\"doi\":\"10.3390/ecmc-4-05604\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Over several years, xanthone derivatives have been the core of several studies, essentially due their wide range of biological and pharmacological activities [1]. Recently, chiral derivatives of xanthones (CDXs) have come to arouse great interest considering enantioselectivity studies associated with biological activities [2,3] as well as selectors for chiral stationary phases (CSPs) in liquid chromatography (LC) [4,5]. \\nFrom the perspective of Medicinal Chemistry, some CDXs synthetized by our group revealed interesting biological activities [2,3]. Besides the potential as new drugs, CDXs afford promising LC enantioresolution results [6]. \\nIn a continuation of our study, new enantiomerically pure CDXs were synthetized for biological activity evaluation as well as selectors for new CSPs, confirming that CDXs have important applications not only in the field of Medicinal Chemistry but also for analytical applications. \\nAcknowledgements: \\nThis research was partially supported by the Strategic Funding UID/Multi/04423/2013 and UID/QUI/00062/2013 through national funds provided by FCT and ERDF, in the framework of PT2020, by projects PTDC/MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599-PPCDT), and project No. POCI-01-0145-FEDER-028736, co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF, and by FCT through national funds, as well as by the Portuguese NMR Network, and CHIRALXANT-CESPU-2018. \\n \\n[1] Shagufta, A.I. Eur. J. Med. Chem., 2016, 116, 267-280. \\n[2] Fernandes, C. et al. Bioorg. Med. Chem. 2014, 22, 1049-1062. \\n[3] Fernandes, C. et al. Pharmaceuticals, 2017, 10, 50, doi:10.3390/ph10020050. \\n[4] Phyo, Y.Z. et al. Molecules, 2018, 23, 142, doi:10.3390/molecules23010142. \\n[5] Carraro, M.L. et al. Chirality, 2017, 1–10 \\n[6] Fernandes, C. et al. Chirality, 2017, 29(8),430-442.\",\"PeriodicalId\":20450,\"journal\":{\"name\":\"Proceedings of 4th International Electronic Conference on Medicinal Chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of 4th International Electronic Conference on Medicinal Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/ecmc-4-05604\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ecmc-4-05604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
近年来,山酮衍生物一直是多项研究的核心,主要是由于其广泛的生物学和药理活性[1]。近年来,考虑到与生物活性相关的对映体选择性研究[2,3]以及液相色谱(LC)中手性固定相(CSPs)的选择剂[4,5],口山酮(CDXs)的手性衍生物引起了人们的极大兴趣。从药物化学的角度来看,我们小组合成的一些cdx显示出有趣的生物活性[2,3]。除了作为新药的潜力外,CDXs还提供了有希望的LC对映体拆分结果[6]。在我们的研究中,我们合成了新的对映体纯cdx用于生物活性评价和新的csp的选择器,证实了cdx不仅在药物化学领域而且在分析应用中具有重要的应用。致谢:本研究得到了战略基金UID/Multi/04423/2013和UID/QUI/00062/2013的部分支持,通过FCT和ERDF提供的国家基金,在PT2020框架内,项目PTDC/MAR-BIO/4694/2014(参考文献poci -01-0145- federal -016790;项目编号3599-PPCDT);poci -01-0145-联邦-028736,由COMPETE 2020、葡萄牙2020和欧盟通过ERDF、FCT通过国家基金、葡萄牙核磁共振网络和CHIRALXANT-CESPU-2018共同资助。[1]张志强,张志强。医学化学。中文信息学报,2016,16(1):267-280。[2]张志强,张志强。Bioorg。医学化学,2014,22,1049-1062。[3]张志强,张志强。医药,2017,10,50,doi:10.3390/ph10020050。[4]刘永忠,刘永忠,等。分子学报,2018,23,142,doi:10.3390/molecules23010142。[5]张晓明,张晓明。李建军,张建军,等。手性研究进展[6]。手性,2017,29(8),430-442。
Dual application of chiral derivatives of xanthones in medicinal chemistry and liquid chromatography
Over several years, xanthone derivatives have been the core of several studies, essentially due their wide range of biological and pharmacological activities [1]. Recently, chiral derivatives of xanthones (CDXs) have come to arouse great interest considering enantioselectivity studies associated with biological activities [2,3] as well as selectors for chiral stationary phases (CSPs) in liquid chromatography (LC) [4,5].
From the perspective of Medicinal Chemistry, some CDXs synthetized by our group revealed interesting biological activities [2,3]. Besides the potential as new drugs, CDXs afford promising LC enantioresolution results [6].
In a continuation of our study, new enantiomerically pure CDXs were synthetized for biological activity evaluation as well as selectors for new CSPs, confirming that CDXs have important applications not only in the field of Medicinal Chemistry but also for analytical applications.
Acknowledgements:
This research was partially supported by the Strategic Funding UID/Multi/04423/2013 and UID/QUI/00062/2013 through national funds provided by FCT and ERDF, in the framework of PT2020, by projects PTDC/MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599-PPCDT), and project No. POCI-01-0145-FEDER-028736, co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF, and by FCT through national funds, as well as by the Portuguese NMR Network, and CHIRALXANT-CESPU-2018.
[1] Shagufta, A.I. Eur. J. Med. Chem., 2016, 116, 267-280.
[2] Fernandes, C. et al. Bioorg. Med. Chem. 2014, 22, 1049-1062.
[3] Fernandes, C. et al. Pharmaceuticals, 2017, 10, 50, doi:10.3390/ph10020050.
[4] Phyo, Y.Z. et al. Molecules, 2018, 23, 142, doi:10.3390/molecules23010142.
[5] Carraro, M.L. et al. Chirality, 2017, 1–10
[6] Fernandes, C. et al. Chirality, 2017, 29(8),430-442.